RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
We have previously shown that [F-18]norchlorofluoroepibatidine ([F-18]NFEP) would be an ideal radiotracer for positron emission tomography (PET) imaging of nicotinic acetylcholine receptors (nAChR); however, its high toxicity is a limiting factor for human studies. We, therefore, synthesized its N-methyl derivative ([F-18]N-Me-NFEP) and carried out comparative studies. The distribution volumes for different brain regions were higher for [F-18]N-Me-NFEP than those for [F-18]NFEP (average: 52.5 +/- 0.9 vs. 36.4 +/- 0.7 for thalamus), though the distribution volume (DV) ratios were similar (3.93 +/- 0.27 vs. 3.65 +/- 0.19 for thalamus to cerebellum). Treatment with nicotine reduced the binding of both radiotracers. Toxicology studies in awake rats showed that N-methyl-NFEP has a lower mortality (0 vs. 30%) and smaller effect on plasma catecholamines than NFEP at a dose of 1.5 mu g/kg, However, marked alterations in cardiorespiratory parameters were observed after injection of N-methyl-NFEP (0.5 mu g/kg, IV) to an awake dog, Our results suggest that although the binding characteristics of [F-18]NFEP and [F-18]N-Me-NFEP appear to be ideally suited for PET imaging studies of the human brain, their relatively small safety margin will limit their use in humans. NUCL MED BIOL 26;1:139-148, 1999. (C) 1999 Elsevier Science Inc